Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With Obsessive Compulsive Disorder (OCD)
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 5/21/2016 |
| Start Date: | June 2014 |
| End Date: | June 2017 |
Obsessive-compulsive disorder (OCD) is a common illness that causes significant distress and
impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that
are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3
months), and even then they usually only partially reduce OCD symptoms. The present study,
will test if intranasal ketamine is feasible to use and can reduce OCD symptoms
significantly more than a comparison medication called midazolam. Therefore, you may or may
not receive ketamine as part of this study. Results from this study will allow doctors and
researchers to better understand if you and others with OCD may respond to this class of
medications.
impairment. Currently, serotonin reuptake inhibitors (SRIs) are the only medications that
are FDA-approved to treat OCD. Unfortunately, SRIs can take a long time to work (2-3
months), and even then they usually only partially reduce OCD symptoms. The present study,
will test if intranasal ketamine is feasible to use and can reduce OCD symptoms
significantly more than a comparison medication called midazolam. Therefore, you may or may
not receive ketamine as part of this study. Results from this study will allow doctors and
researchers to better understand if you and others with OCD may respond to this class of
medications.
Inclusion Criteria:
- Age 18-55
- Physically healthy and not currently pregnant
- Primary diagnosis of OCD
- Sufficient severity of symptoms
- For all patients on medications, medications dose must be stable for at least 6 weeks
prior to enrollment. Must discuss with Dr. current medications and doses.
- Able to provide consent
Exclusion Criteria:
- First degree relative with schizophrenia
- Psychiatric conditions that would make participation unsafe determined by study
doctor
- Female patients who are either pregnant or nursing
- Planning to start EX/RP during the period of the study or those who have completed an
adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks
prior to enrollment.
- Nasal obstruction or history of nasal surgery
- Currently on psychotropic medication or other medication likely to interact with the
glutamate system
- Medical conditions that make participation unsafe
- Allergy or intolerance to ketamine or midazolam
We found this trial at
1
site
New York State Psychiatric Institute The New York State Psychiatric Institute (NYSPI), established in 1895,...
Click here to add this to my saved trials
